BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma
- PMID: 30863114
- PMCID: PMC6391130
- DOI: 10.2147/OTT.S190001
BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma
Abstract
Purpose: Fine-needle aspiration biopsy (FNAB) is regarded by the Bethesda system as the gold-standard investigation for stratifying the risk of malignancy of a thyroid nodule. However, some limitations affect the adequacy of the obtained materials, resulting in 30% of the cytological results remaining in the indeterminate category. We aimed to investigate the diagnostic value of the BRAF mutation in cytologically indeterminate thyroid nodules after the reclassification of a variant thyroid carcinoma.
Patients and methods: In this prospective diagnostic study, 76 patients with FNAB findings of atypia of undetermined significance (AUS) and suspicious for malignancy (SUS) were included. The BRAF V600 mutation from FNAB was confirmed by a PCR-based method (Sanger sequencing combined with allele-specific real-time PCR techniques) and immunohistochemistry (IHC). Pathological specimens and features, including noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), were reviewed and compared to the FNAB results.
Results: Using the PCR-based method, the BRAF mutation was positive in 13/76 cases (17.1%), with the diagnostic values of 16.7% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 82.8% negative predictive value (NPV) in the AUS compared to 73.3% sensitivity, 100% specificity, 100% PPV, and 20% NPV in the SUS. For the IHC technique, only 20 of the 76 cytological specimens were qualified for testing. The BRAF mutation was positive in 13/20 cases, with the diagnostic values of 100% sensitivity, 63.6% specificity, 42.9% PPV, and 100% NPV in the AUS compared to 100% sensitivity and PPV in the SUS. The BRAF mutation was not found in the pathological reports for NIFTP.
Conclusion: The malignancy rate is high in our data, with specific and acceptable accuracy rates for the BRAF mutation from FNAB found by using the PCR-based method. NIFTP has been introduced after the pathological reclassification. Molecular diagnosis might be useful to establish the nature of the disease.
Keywords: BRAF mutation; NIFTP; Thailand; fine-needle aspiration; indeterminate thyroid nodules; noninvasive follicular thyroid neoplasm with papillary-like nuclear features; papillary thyroid carcinoma.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures






Similar articles
-
Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" and their correlation with tumor histology.Hum Pathol. 2016 Aug;54:134-42. doi: 10.1016/j.humpath.2016.03.014. Epub 2016 Apr 13. Hum Pathol. 2016. PMID: 27085556
-
Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules.Cancer Cytopathol. 2018 Feb;126(2):86-93. doi: 10.1002/cncy.21922. Epub 2017 Sep 15. Cancer Cytopathol. 2018. PMID: 28914983
-
RISK OF MALIGNANCY IN THYROID CYTOLOGY: THE IMPACT OF THE RECLASSIFICATION OF NONINVASIVE FOLLICULAR THYROID NEOPLASM WITH PAPILLARY-LIKE NUCLEAR FEATURES (NIFTP).Endocr Pract. 2019 Jul;25(7):642-647. doi: 10.4158/EP-2018-0423. Epub 2019 Mar 13. Endocr Pract. 2019. PMID: 30865528
-
Cytological Diagnoses Associated with Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features According to the Bethesda System for Reporting Thyroid Cytopathology: A Systematic Review and Meta-Analysis.Thyroid. 2019 Feb;29(2):222-228. doi: 10.1089/thy.2018.0394. Epub 2018 Dec 21. Thyroid. 2019. PMID: 30426887
-
High risk of malignancy in cases with atypia of undetermined significance on fine needle aspiration of thyroid nodules even after exclusion of NIFTP.Diagn Cytopathol. 2020 Nov;48(11):986-997. doi: 10.1002/dc.24533. Epub 2020 Aug 3. Diagn Cytopathol. 2020. PMID: 32745375
Cited by
-
Risk assessment of cytologically indeterminate thyroid nodules with integrated molecular testing and repeat biopsy: a surgical decision-oriented tool.World J Surg Oncol. 2023 Feb 3;21(1):34. doi: 10.1186/s12957-023-02917-x. World J Surg Oncol. 2023. PMID: 36737779 Free PMC article.
-
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAF V600E Mutation.Onco Targets Ther. 2021 Jun 29;14:3959-3969. doi: 10.2147/OTT.S308910. eCollection 2021. Onco Targets Ther. 2021. PMID: 34234465 Free PMC article.
-
Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features.J Med Life. 2022 Apr;15(4):520-525. doi: 10.25122/jml-2021-0415. J Med Life. 2022. PMID: 35646190 Free PMC article.
-
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.Endocr Pathol. 2020 Mar;31(1):57-66. doi: 10.1007/s12022-019-09596-z. Endocr Pathol. 2020. PMID: 31811566
References
-
- Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328(8):553–559. - PubMed
-
- Agate L, Lorusso L, Elisei R. New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. J Endocrinol Invest. 2012;35(6 Suppl):3–9. - PubMed
-
- Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009;19(11):1159–1165. - PubMed
-
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. - PMC - PubMed
-
- Zhang M, Lin O. Molecular testing of thyroid nodules: a review of current available tests for fine-needle aspiration specimens. Arch Pathol Lab Med. 2016;140(12):1338–1344. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials